生長(zhǎng)激素釋放激素（GHRH）是下丘腦分泌的一種神經(jīng)肽類(lèi)激素，通過(guò)作用于垂體的生長(zhǎng)激素釋放激素受體（GHRHR）調(diào)節(jié)生長(zhǎng)激素的分泌和合成，進(jìn)而調(diào)節(jié)細(xì)胞生長(zhǎng)。研究表明，GHRHR除在垂體表達(dá)外，也表達(dá)在諸多垂體外組織中，例如心肌組織。近年來(lái)的研究發(fā)現(xiàn)，與內(nèi)源性GHRH相比，人工合成的GHRH類(lèi)似物（GHRH-A）具有受體親和力強(qiáng)，半衰期長(zhǎng)和不良反應(yīng)少等優(yōu)點(diǎn)。研究表明GHRH-A對(duì)多種實(shí)驗(yàn)性心血管疾?。–VDs），如心力衰竭、心肌缺血/再灌注損傷和血管鈣化等具有保護(hù)效應(yīng)，提示該類(lèi)藥物具有治療CVDs的潛在價(jià)值。綜述GHRH/GHRHR信號(hào)通路傳導(dǎo)機(jī)制，內(nèi)源性GHRH及GHRH-A對(duì)心肌細(xì)胞的保護(hù)效應(yīng)以及在治療CVDs中的作用及機(jī)制。

Growth hormone releasing hormone (GHRH) is a neuropeptide hormone secreted by the hypothalamus, which regulates the secretion and synthesis of growth hormone by stimulating GHRH receptor (GHRHR) in the pituitary gland, promoting cell growth. Except in the pituitary gland, GHRHR is also expressed in many extrapituitary tissues, including myocardial tissue. Compared with endogenous GHRH, synthesized GHRH analogues (GHRH-A) exhibit stronger receptor affinity, longer half-life, and fewer side effects. It has been shown that GHRH-A can exert beneficial effects on various experimental cardiovascular diseases (CVDs), such as heart failure, myocardial ischemia/reperfusion injury, and vascular calcification, suggesting that GHRH-As have potential for treating CADs. This article reviews the GHRH/GHRHR signaling pathway, the protective effects of endogenous GHRH and synthetic GHRH-As on myocardial cells, and their roles and underlying potential mechanisms in the treatment of CVDs.

R973

國(guó)家自然科學(xué)基金面上項(xiàng)目（82270434， 81970357）；遼寧省自然科學(xué)基金面上項(xiàng)目（2022-MS-246）